Status:
RECRUITING
Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study
Lead Sponsor:
Incheon St.Mary's Hospital
Collaborating Sponsors:
Yonsei University
Conditions:
Mastectomy
Breast Neoplasm Malignant Primary
Eligibility:
All Genders
19+ years
Brief Summary
Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains ...
Detailed Description
Breast cancer is the most prevalent malignancy among women globally, leading to surgical interventions for non-metastatic cases. While breast cancer generally has a favorable prognosis, achieving nega...
Eligibility Criteria
Inclusion
- Adult patients (≥ 19 years old) diagnosed with breast cancer (invasive and in situ).
- Patients scheduled for surgical resection of the tumor Availability of both preoperative tumor size assessments and pathologic measurements post-surgery
Exclusion
- Patients with recurrent breast cancer Inflammatory breast cancer Patients who did not undergo surgery Patients whose preoperative tumor size data is not available or deficient for analyzing
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06505577
Start Date
August 1 2024
End Date
August 30 2027
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Incheon St. Mary's Hospital
Incheon, South Korea